| GHDN Stock | | | EUR 2.69 0.00 0.00% |
COO
Dr. Ralph Kern is Chief Operating Officer and Chief Medical Officer of the company. Prior to joining the Company, Dr. Kern was Senior Vice President, Head Worldwide Medical at Biogen Inc. since 2016. Prior positions at Biogen Inc. include Vice President, Head of Global Therapeutic Areas from 2015 to 2016 and Vice President, Head of Global Medical Neurology in 2015 since 2017.
| Age | 65 |
| Tenure | 7 years |
| Phone | 201 488 0460 |
| Web | https://www.brainstorm-cell.com |
Kern has also served Novartis Pharmaceuticals Corporationration as Vice President, Head Neuroscience Medical Unit from 2014 to 2015 and as Vice President, Head MS Medical Unit from 2011 to 2014. He also worked for Genzyme Corporationration from 2006 to 2011 where he served as Global Medical Director, Personalized Genetic Health, Head of Medical Affairs, Canada, General Manager, Fabry Disease and Head of Medical Affairs, Canada . He also served as University Neurology Program Director at the University of Toronto, Consultant Neurologist at Mount Sinai Hospital and Director, EMG, EEG and Evoked Potential Laboratory at The Credit Valley Hospital .
Brainstorm Cell Management Efficiency
The company has return on total asset
(ROA) of
(0.6831) % which means that it has lost $0.6831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.9343) %, meaning that it generated substantial loss on money invested by shareholders. Brainstorm Cell's management efficiency ratios could be used to measure how well Brainstorm Cell manages its routine affairs as well as how well it operates its assets and liabilities.
Brainstorm Cell Therapeutics has accumulated 3.04
M in total debt with debt to equity ratio
(D/E) of 934.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Brainstorm Cell Ther has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Brainstorm Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Brainstorm Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brainstorm Cell Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brainstorm to invest in growth at high rates of return. When we think about Brainstorm Cell's use of debt, we should always consider it together with cash and equity.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people. Brainstorm Cell Therapeutics (GHDN) is traded on Frankfurt Exchange in Germany and employs 43 people.
Management Performance
Brainstorm Cell Ther Leadership Team
Elected by the shareholders, the Brainstorm Cell's board of directors comprises two types of representatives: Brainstorm Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainstorm. The board's role is to monitor Brainstorm Cell's management team and ensure that shareholders' interests are well served. Brainstorm Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainstorm Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yael Gothelf, VP Affairs | |
| Irit DSc, CoFounder Board | |
| Antal PearlLendner, VP Counsel | |
| Daniel Offen, Chief Advisor | |
| Stacy Lindborg, Exec Officer | |
| Ralph Kern, COO and Chief Medical Officer | |
| Chaim Lebovits, President CEO | |
| PharmD MBA, Ex COO | |
| Uri Yablonka, Executive Vice President Chief Business Officer, Director | |
Brainstorm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainstorm Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.